News

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06 ...